"use strict";(self.webpackChunkBenStockTracker=self.webpackChunkBenStockTracker||[]).push([[1745],{1745:e=>{e.exports=JSON.parse('{"cc87734f-bbb6-368e-a99b-0c68fd301ce6":{"uuid":"cc87734f-bbb6-368e-a99b-0c68fd301ce6","title":"J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance","publisher":"Zacks","link":"https://finance.yahoo.com/news/j-j-jnj-beats-q2-132501120.html","providerPublishTime":1658237101,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/6hgtO7luBTc3xSFU5hzSIg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/UjHemYIeF2aWxwD7gqDihg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/4K8GabCkmtDgO.0ZkJi.oQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/UjHemYIeF2aWxwD7gqDihg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["JNJ","ABBV"]},"61afe8d5-0043-3c2f-a795-f0a530194b09":{"uuid":"61afe8d5-0043-3c2f-a795-f0a530194b09","title":"3 Dividend Growth Stocks You Can Buy Now and Hold Forever","publisher":"Motley Fool","link":"https://finance.yahoo.com/m/61afe8d5-0043-3c2f-a795-f0a530194b09/3-dividend-growth-stocks-you.html","providerPublishTime":1658221980,"type":"STORY","relatedTickers":["ABT","ABBV","JNJ"]},"ee46ae4e-605c-3332-8521-53f6e971e60c":{"uuid":"ee46ae4e-605c-3332-8521-53f6e971e60c","title":"AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine","publisher":"Zacks","link":"https://finance.yahoo.com/news/abbvie-abbv-seeks-eu-nod-152003745.html","providerPublishTime":1658157603,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/sBy0Jqrq1puvNI83AuaseQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/J5PJq8rtkuiBcDVdnbD5LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/rFj6uz1yhoLFyrXhNS1E4Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/J5PJq8rtkuiBcDVdnbD5LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","BHVN","PFE","MRK"]},"94f7f15d-d7b9-3bd5-bea9-50b8fb665167":{"uuid":"94f7f15d-d7b9-3bd5-bea9-50b8fb665167","title":"AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022","publisher":"Benzinga","link":"https://finance.yahoo.com/news/abbvie-submit-european-application-epcoritamab-150515984.html","providerPublishTime":1658156715,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/YZRdUeIln0c6gb2qtn2niw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/HlgWiNP59PVBUu6r6dwNXA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5fda512e9023d444ae7f8fde8e71fefb","width":600,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/WWMzx8.xUWBpbSupGl8KHg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/HlgWiNP59PVBUu6r6dwNXA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5fda512e9023d444ae7f8fde8e71fefb","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","GMAB.CO"]},"074241fa-f39f-3eea-bb87-4910ac77ace3":{"uuid":"074241fa-f39f-3eea-bb87-4910ac77ace3","title":"Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody\xae-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","publisher":"Business Wire","link":"https://finance.yahoo.com/news/genmab-announces-abbvie-submit-marketing-140500954.html","providerPublishTime":1658153100,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/BWJ8AtjLjy57MNH9r1NqxA--~B/aD0xNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Tl.gCggKfotTM7YpzH4mJg--~B/aD0xNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/af19af4b570605c4b13c2b1f564a3d9f","width":480,"height":140,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/iOE.gl_fGqk3ulq1Jn.2dw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/Tl.gCggKfotTM7YpzH4mJg--~B/aD0xNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/af19af4b570605c4b13c2b1f564a3d9f","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","GMAB","GNMSF"]},"b5f47650-edf3-3d58-98f9-792973e21825":{"uuid":"b5f47650-edf3-3d58-98f9-792973e21825","title":"AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine","publisher":"PR Newswire","link":"https://finance.yahoo.com/news/abbvie-submits-marketing-authorization-application-060000051.html","providerPublishTime":1658124000,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/GN_Xl89uM6tiRu8tc.R6Ow--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/_NM4E2ajsJ1_0peYy9chdg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/bc66733d647f2147db0060991729537c","width":16,"height":16,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/Dhwp4AsXRwu3PagbD.bKVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/_NM4E2ajsJ1_0peYy9chdg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/bc66733d647f2147db0060991729537c","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]},"8371ec0c-d18c-38a9-bac4-24869ee8c220":{"uuid":"8371ec0c-d18c-38a9-bac4-24869ee8c220","title":"3 Dividend Growth Stocks to Buy in July","publisher":"Motley Fool","link":"https://finance.yahoo.com/m/8371ec0c-d18c-38a9-bac4-24869ee8c220/3-dividend-growth-stocks-to.html","providerPublishTime":1658051880,"type":"STORY","relatedTickers":["JNJ","ABBV","ABT","^GSPC"]},"ddb044b0-a5da-36d8-b7c5-3df01f4960f7":{"uuid":"ddb044b0-a5da-36d8-b7c5-3df01f4960f7","title":"Dow Jones Giant UnitedHealth Breaks Out, Leading 5 Stocks To Watch","publisher":"Investor\'s Business Daily","link":"https://finance.yahoo.com/m/ddb044b0-a5da-36d8-b7c5-3df01f4960f7/dow-jones-giant-unitedhealth.html","providerPublishTime":1657972837,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/caqcTqmyuwIJNW2gDx5Nyw--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/PANDoIrKWVp6TtVKQKjkbQ--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/82f02432bd7c514ef079283199618114","width":1012,"height":572,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/HO7uI20J8IpBPVsj8WQF4w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/PANDoIrKWVp6TtVKQKjkbQ--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/82f02432bd7c514ef079283199618114","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","UNH","SWAV","LI","DLTR"]}}')}}]);